Technology ID
TAB-3584
Formulation of a Modified Stable FGF-1 (TTHX1114) to Accelerate Corneal Endothelium Regeneration
E-Numbers
E-038-2021-0
Lead Inventor
Eveleth, David (Trefoil Therapeutics, Inc)
Co-Inventors
Vyas, Vinay (NCI)
Dong, Hui Fang (NCI)
Alimardanov, Asaf (NCATS)
Mitra, Gautam ("George") (NCI)
Broadt, Trevor (NCI)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Endocrinology
Dental
Cardiology
Lead IC
NCATS
ICs
NCI
NCATS
This technology includes the use of a novel formulation for an engineered version of Fibroblast Growth Factor 1 (FGF1), TTHX1114, that can be used to accelerate regeneration of the corneal endothelium after surgical lesions. FGFs are well-established regulators of migration and proliferation of corneal endothelial cells (CECs).
Commercial Applications
The engineered FGF1, TTHX1114, is currently being commercialized.
Competitive Advantages
Fibroblast growth factors 1 and 2 are currently used to accelerate healing in ocular surface wounds. These FGFs have three cystine residues that can lead to inactivation of the factor. The formulations in this technology remove these residues and result in the stable preservation of a functionally active recombinant FGF-1 (TTHX1114).
Licensing Contact: